Floatz logo

44 assets in Nasopharyngeal Carcinoma

Therapeutic assets addressing Nasopharyngeal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Irinotecan
Nasopharyngeal Carcinoma
M.D. Anderson Cancer CenterP2B (60)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide
Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P2B (58)
Ipilimumab
Nasopharyngeal Carcinoma
Xencor, Inc.P2B (58)
[18f]f-resca-rt4
Nasopharyngeal Carcinoma
RenJi HospitalP2/3B (57)
[18F]F-RESCA-T4
Nasopharyngeal Carcinoma
RenJi HospitalP2/3B (57)
[68ga]ga-nota-rt4
Nasopharyngeal Carcinoma
RenJi HospitalP2/3B (57)
[68ga]ga-nota-t4
Nasopharyngeal Carcinoma
RenJi HospitalP2/3B (57)
Dexasone
Nasopharyngeal Carcinoma
TakedaP1/2CCC (55)
[18F]F-RESCA-R8B4
Nasopharyngeal Carcinoma
RenJi HospitalP2CCC (53)
[18F]F-RESCA-RCCB6
Nasopharyngeal Carcinoma
RenJi HospitalP2CCC (53)
[18F]F-RESCA-RD06
Nasopharyngeal Carcinoma
RenJi HospitalP2CCC (53)
[68ga]ga-nota-r8b4
Nasopharyngeal Carcinoma
RenJi HospitalP2CCC (53)
[68ga]ga-nota-rd06
Nasopharyngeal Carcinoma
RenJi HospitalP2CCC (53)
Atezolizumab
Nasopharyngeal Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Nivolumab
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pembrolizumab
Nasopharyngeal Carcinoma
Novartis PharmaceuticalsP1/2CCC (53)
Si-B003
Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.P2CCC (53)
Cyclophosphamide
Nasopharyngeal Carcinoma
Zhejiang UniversityP1/2CCC (50)
Fludarabine
Nasopharyngeal Carcinoma
Zhejiang UniversityP1/2CCC (50)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Nasopharyngeal Carcinoma
VM Oncology, LLCP1/2CCC (48)
Cetuximab
Nasopharyngeal Carcinoma
Hummingbird BioscienceP1/2CCC (48)
Docetaxel
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Nasopharyngeal Carcinoma
Hummingbird BioscienceP1/2CCC (48)
Tak-500
Nasopharyngeal Carcinoma
TakedaP1/2CC (47)
Tocilizumab
Nasopharyngeal Carcinoma
TakedaP1/2CC (47)
gen1160
Nasopharyngeal Carcinoma
GenmabP1/2CC (45)
ilb2109
Nasopharyngeal Carcinoma
Innolake BiopharmP1/2CC (45)
SX682
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CC (45)
Toripalimab
Nasopharyngeal Carcinoma
Innolake BiopharmP1/2CC (45)
P-Muc1C-Allo1 Car-T Cells
Nasopharyngeal Carcinoma
Poseida Therapeutics, Inc.P1CC (43)
Rimiducid
Nasopharyngeal Carcinoma
Poseida Therapeutics, Inc.P1CC (43)
[212pb]vmt-alpha-net
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)P1CC (41)
Anti-Egfr Antibody-Drug Conjugate Mrg003
Nasopharyngeal Carcinoma
Sun Yat-sen UniversityP1CC (41)
Apg-5918
Nasopharyngeal Carcinoma
Ascentage Pharma Group Inc.P1CC (41)
cht101
Nasopharyngeal Carcinoma
Zhejiang UniversityP1CC (41)
dky709
Nasopharyngeal Carcinoma
Novartis PharmaceuticalsP1CC (41)
kfa115
Nasopharyngeal Carcinoma
Novartis PharmaceuticalsP1CC (41)
Mabel Ctls
Nasopharyngeal Carcinoma
Baylor College of MedicineP1CC (41)
Oxodotreotide
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)P1CC (41)
Valganciclovir
Nasopharyngeal Carcinoma
Viracta Therapeutics, Inc.P1CC (41)
Spartalizumab
Nasopharyngeal Carcinoma
Novartis PharmaceuticalsP1C (39)
Nanatinostat
Nasopharyngeal Carcinoma
Viracta Therapeutics, Inc.P1C (37)
Avzo-1418
Nasopharyngeal Carcinoma
Avenzo Therapeutics, Inc.P1/2NR ()